These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35507888)

  • 1. Activity of Pemigatinib in Pilocytic Astrocytoma and
    Capone S; Ketonen L; Weathers SP; Subbiah V
    JCO Precis Oncol; 2022 Apr; 6():e2100371. PubMed ID: 35507888
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/
    Manur R; Sung PJ; Loren AW; Ritchie EK; Frank D; Bagg A; Geyer JT; Bogusz AM
    Leuk Lymphoma; 2020 Feb; 61(2):450-454. PubMed ID: 31524018
    [No Abstract]   [Full Text] [Related]  

  • 3. Sensitive detection of FGFR1 N546K mosaic mutation in patient with encephalocraniocutaneous lipomatosis and pilocytic astrocytoma.
    Kordacka J; Zakrzewski K; Gruszka R; Witusik-Perkowska M; Taha J; Sikorska B; Liberski PP; Zakrzewska M
    Am J Med Genet A; 2019 Aug; 179(8):1622-1627. PubMed ID: 31173478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
    Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
    Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
    Liu PCC; Koblish H; Wu L; Bowman K; Diamond S; DiMatteo D; Zhang Y; Hansbury M; Rupar M; Wen X; Collier P; Feldman P; Klabe R; Burke KA; Soloviev M; Gardiner C; He X; Volgina A; Covington M; Ruggeri B; Wynn R; Burn TC; Scherle P; Yeleswaram S; Yao W; Huber R; Hollis G
    PLoS One; 2020; 15(4):e0231877. PubMed ID: 32315352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemigatinib: First Approval.
    Hoy SM
    Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor.
    Wu L; Zhang C; He C; Qian D; Lu L; Sun Y; Xu M; Zhuo J; Liu PCC; Klabe R; Wynn R; Covington M; Gallagher K; Leffet L; Bowman K; Diamond S; Koblish H; Zhang Y; Soloviev M; Hollis G; Burn TC; Scherle P; Yeleswaram S; Huber R; Yao W
    J Med Chem; 2021 Aug; 64(15):10666-10679. PubMed ID: 34269576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epilepsy-associated glioneuronal tumor with mixed morphology harboring FGFR1 mutation.
    Yamada S; Nobusawa S; Yamazaki T; Teranishi T; Watanabe S; Murayama K; Ohba S; Okabe A; Sakurai K; Urano M; Tsukamoto T; Yokoo H; Hirose Y; Abe M
    Pathol Int; 2019 Jun; 69(6):372-377. PubMed ID: 31218776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
    Jones DT; Hutter B; Jäger N; Korshunov A; Kool M; Warnatz HJ; Zichner T; Lambert SR; Ryzhova M; Quang DA; Fontebasso AM; Stütz AM; Hutter S; Zuckermann M; Sturm D; Gronych J; Lasitschka B; Schmidt S; Seker-Cin H; Witt H; Sultan M; Ralser M; Northcott PA; Hovestadt V; Bender S; Pfaff E; Stark S; Faury D; Schwartzentruber J; Majewski J; Weber UD; Zapatka M; Raeder B; Schlesner M; Worth CL; Bartholomae CC; von Kalle C; Imbusch CD; Radomski S; Lawerenz C; van Sluis P; Koster J; Volckmann R; Versteeg R; Lehrach H; Monoranu C; Winkler B; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; Ebinger M; Schuhmann MU; Cho YJ; Pomeroy SL; von Deimling A; Witt O; Taylor MD; Wolf S; Karajannis MA; Eberhart CG; Scheurlen W; Hasselblatt M; Ligon KL; Kieran MW; Korbel JO; Yaspo ML; Brors B; Felsberg J; Reifenberger G; Collins VP; Jabado N; Eils R; Lichter P; Pfister SM;
    Nat Genet; 2013 Aug; 45(8):927-32. PubMed ID: 23817572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors.
    Engelhardt S; Behling F; Beschorner R; Eckert F; Kohlhof P; Tatagiba M; Tabatabai G; Schuhmann MU; Ebinger M; Schittenhelm J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):857-866. PubMed ID: 35018490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGFR1 mutations in Rosette-forming glioneuronal tumors of the fourth ventricle.
    Gessi M; Moneim YA; Hammes J; Goschzik T; Scholz M; Denkhaus D; Waha A; Pietsch T
    J Neuropathol Exp Neurol; 2014 Jun; 73(6):580-4. PubMed ID: 24806303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
    Lucas CG; Gupta R; Doo P; Lee JC; Cadwell CR; Ramani B; Hofmann JW; Sloan EA; Kleinschmidt-DeMasters BK; Lee HS; Wood MD; Grafe M; Born D; Vogel H; Salamat S; Puccetti D; Scharnhorst D; Samuel D; Cooney T; Cham E; Jin LW; Khatib Z; Maher O; Chamyan G; Brathwaite C; Bannykh S; Mueller S; Kline CN; Banerjee A; Reddy A; Taylor JW; Clarke JL; Oberheim Bush NA; Butowski N; Gupta N; Auguste KI; Sun PP; Roland JL; Raffel C; Aghi MK; Theodosopoulos P; Chang E; Hervey-Jumper S; Phillips JJ; Pekmezci M; Bollen AW; Tihan T; Chang S; Berger MS; Perry A; Solomon DA
    Acta Neuropathol Commun; 2020 Aug; 8(1):151. PubMed ID: 32859279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201.
    Necchi A; Pouessel D; Leibowitz R; Gupta S; Fléchon A; García-Donas J; Bilen MA; Debruyne PR; Milowsky MI; Friedlander T; Maio M; Gilmartin A; Li X; Veronese ML; Loriot Y
    Ann Oncol; 2024 Feb; 35(2):200-210. PubMed ID: 37956738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo.
    Jiang K; Tang X; Guo J; He R; Chan S; Song X; Tu Z; Wang Y; Ren X; Ding K; Zhang Z
    Cancer Med; 2021 Jul; 10(14):4874-4884. PubMed ID: 34114373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation.
    Sievers P; Schrimpf D; Stichel D; Reuss DE; Hasselblatt M; Hagel C; Staszewski O; Hench J; Frank S; Brandner S; Korshunov A; Wick W; Pfister SM; Reifenberger G; von Deimling A; Sahm F; Jones DTW
    Acta Neuropathol; 2020 Feb; 139(2):403-406. PubMed ID: 31729570
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
    Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT).
    Gessi M; Abdel Moneim Y; Hammes J; Waha A; Pietsch T
    Acta Neuropathol; 2014; 127(6):935-6. PubMed ID: 24777483
    [No Abstract]   [Full Text] [Related]  

  • 20.
    Ballester LY; Penas-Prado M; Leeds NE; Huse JT; Fuller GN
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.